

digestive tract, said at least one lytic enzyme having the ability to digest a cell wall of a specific said bacteria, said bacteria being selected from the group consisting of *Listeria*, *Salmonella*, *E. coli*, *Campylobacter*, and combinations thereof;

ii) mixing said at least one lytic enzyme produced in step (a) with a suppository carrier for delivering said at least one enzyme to said digestive tract.

16) (currently amended) The suppository [enema] according to claim 15, wherein said composition further comprises a buffer that maintains pH of a composition a range between about 4.0 and about 9.0.

17) (currently amended) The suppository [enema] according to claim 16, wherein the buffer maintains the pH of the composition at the range between 5.5 and 7.5.

18) (currently amended) The suppository [enema] according to claim 18, wherein said buffer comprises a reducing reagent.

19) (currently amended) The suppository [enema] according to claim 20, wherein said reducing reagent is dithiothreitol.

20) (currently amended) The suppository [enema] according to claim 20, wherein said buffer comprises a metal chelating reagent.

21) (currently amended) The suppository [enema] according to claim 22, wherein said metal chelating reagent is ethylenediaminetetracetic disodium salt.

22) (currently amended) The suppository [enema] according to claim 20, wherein said buffer is a citrate-phosphate buffer.

23) (currently amended) The suppository [enema] according to claim 15, further comprising a bactericidal or bacteriostatic agent as a preservative.

24) (currently amended) The suppository [enema] according to claim 15, wherein said at least one lytic enzyme is lyophilized.

25) (currently amended) The suppository [enema] according claim 15, wherein said at least one lytic enzyme is present in a concentration of about 100 to about 100,000 active enzyme units per milliliter of fluid in the wet environment of the digestive tract

26) (currently amended) The suppository [enema] according to claim 25, wherein said at least one lytic enzyme is present in a concentration of about 100 to about 10,000 active enzyme units per milliliter of fluid in the wet environment of the digestive tract.

27) (currently amended) A suppository [enema] for treating bacterial infections of the digestive tract, said suppository enema comprising:

a) an effective amount of at least one specific lytic enzyme genetically coded for by a bacteriophage specific for a specific bacteria selected from the group consisting of *Listeria*, *Salmonella*, *E. coli*, and *Campylobacter*, wherein said at least one said specific lytic enzyme is specific for and has the ability to digest a cell wall of one of said specific bacteria, said specific lytic enzyme being genetically coded for by the same said bacteriophage capable of infecting said specific bacteria being digested; and

b) a suppository carrier capable for delivering said at least one said specific lytic enzyme to said digestive tract.

28) (currently amended) The suppository [enema] according to claim 27, wherein said composition further comprises a buffer that maintains pH of a composition a range between about 4.0 and about 9.0.

29) (currently amended) The suppository [enema] according to claim 28, wherein the buffer maintains the pH of the composition at the range between 5.5 and 7.5.

30) (currently amended) The suppository [enema] according to claim 28, wherein said buffer comprises a reducing reagent.

31) (currently amended) The suppository [enema] according to claim 30, wherein said reducing agent is dithiothreitol.

32) (currently amended) The suppository [enema] according to claim 28, wherein said buffer is a metal chelating agent.

33) (currently amended) The suppository [enema] according to claim 31, wherein said metal chelating reagent is ethylenediaminetetracetic disodium salt.

34) (currently amended) The suppository [enema] according to claim 28, wherein said buffer is a citrate-phosphate buffer.

35) (currently amended) The suppository [enema] according to claim 27, further comprising a bactericidal or bacteriostatic agent as a preservative.

36) (currently amended) The suppository [enema] according to claim 27, wherein said at least one lytic enzyme is lyophilized.

37) (currently amended) The suppository [enema] according to claim 27, wherein said at least one lytic enzyme is present in a concentration of about 100 to about 100,000 active enzyme units per milliliter of fluid in the wet environment of the digestive tract.


38) (currently amended) The suppository [enema] according to claim 37, wherein said at least one lytic enzyme is present in a concentration of about 100 to about 10,000 active enzyme units per milliliter of fluid in the wet environment of the digestive tract.

RESPONSE

The present invention teaches a suppository which contains lytic enzymes which are specific for specific bacteria. Each lytic enzyme is specific for only one specific bacteria. The use of the term "enema" in the claims was an error. Support for the suppository is found on page 14, line 6 of the specification.

The application is now in condition for allowance. Please call the undersigned at (301) 603-9071 if you have any questions or comments. Thank you.

Very truly yours,



Jonathan E. Grant
Reg. No. 34,830

2107 Hounds Run Place
Silver Spring, Maryland 20906
301-603-9071